Galapagos presents clean drug-drug interaction profile with GLPG0634 (filgotinib) at ACR 2014

Published : Monday, November 17, 2014

Galapagos NV, a clinical stage biotech company focused on developing novel mode of action medicines, announces that it will present data supporting the safe use and absence of drug-drug interactions of GLPG0634 (filgotinib) with drugs commonly prescribed for rheumatoid arthritis (RA) patients. In addition, Galapagos will show support for the dose selection in the Phase 2B DARWIN program and present the reversals of RA disease gene expression in patients treated with GLPG0634.

Bètabanenmarkt March 18th

Published : Friday, November 14, 2014

On the 18th of March 2015 the annual science career event of the Leiden University (titled Bètabanenmarkt) will take place. This career event is a great place to meet enthusiastic students ranging from bachelor students to postdocs.

Leiden grants Naturalis funds and land

Published : Wednesday, November 12, 2014

The municipality of Leiden sells a parcel of land to Naturalis Biodiversity Center that plans a large-scale and spectacular renewal. Leiden also gives € 1 million to the museum of which € 450,000 for the purchase of the skeleton of Tyrannosaurus rex.

Galapagos completes recruitment for Darwin 1 study with GLPG0634 (filgotinib) in RA

Published : Wednesday, November 12, 2014

Galapagos NV, a clinical stage biotech company focused on developing novel mode of action medicines, announces that recruitment of rheumatoid arthritis (RA) patients for the Darwin 1 Phase 2B study with GLPG0634 has been completed.

Facio raises €2 million

Published : Thursday, November 6, 2014

Facio Therapies has secured €2 million (about US$ 2.5 million) in initial financing from founding investors Kees van der Graaf and Bill Moss AM. Facio will use these funds towards its drug development program, which is aimed at stopping the progression of FSHD.

GSK discloses good efficacy in psoriasis with GSK2856184

Published : Thursday, November 6, 2014

Galapagos NV, a clinical stage biotech company focused on developing novel mode of action medicines, announces that GSK has disclosed on its website the Phase 2 psoriasis study results with selective JAK1inhibitor GSK2856184, licensed from Galapagos. The results show higher efficacy than those published for apremilast, a recently approved oral medicine for psoriasis and psoriatic arthritis.

Batavia Bioservices nominated 2014 Award of High Growth Company

Published : Wednesday, November 5, 2014

Batavia Bioservices is nominated for the 2014 Award of High Growth Company. This Award is an initiative from Port4Growth with as partners Rabobank and Grant Thornton.
The winners will be announced November 19, 2014.

Price for Leiden natal care

Published : Tuesday, November 4, 2014

The “Verloskundig SamenwerkingsVerband Leiden" (VSV) (Obstetric Collaborative Leiden), has won the national award for the most groundbreaking VSV of the Netherlands. Talmor, national organization in the field of care, grants the award.
> Read more in Dutch

Dutch Space renamed Airbus Defence and Space Netherlands

Published : Monday, November 3, 2014

As of November, Dutch Space, supplier of high tech products and services for the international aerospace industry, will be known under the name of Airbus Defence and Space Netherlands B.V. The change of name of the Dutch company, which plays a leading role in space since the late sixties, stems from the rebranding of the parent company early this year. The new company name, which will be visible today with the new corporate identity and the launch of the website, has no further effect on the Leiden based organization and its employees.

Pharming and Salix announce the launch of Ruconest® in the U.S. for the treatment of acute angioedema attacks in patients with Hereditary Angioedema (HAE)

Published : Monday, November 3, 2014

Pharming Group NV and Salix Pharmaceuticals, Ltd. announced the launch of RUCONEST® (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg in the United States for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE). Effectiveness in clinical studies was not established in HAE patients with laryngeal attacks. This announcement follows the July approval of the drug by the Food and Drug Administration.

Condi food wins Herman Wijffels Innovation Award 2014

Published : Friday, October 31, 2014

Condi food has won the Herman Wijffels Innovation Award 2014 in the category Agri & Food. There were more than 600 subscription in 3 categories. Condi food is a joint venture of cosine measurement systems and Jan Rolloos Ventures, and develops and supplies advanced camera inspection systems for the food industry.

Unique wing patterns make identification of bee species possible

Published : Thursday, October 30, 2014

The advent of DNA barcoding techniques speeded up the identification and characterization of new species and yielded many new insights. However, these techniques are not always applicable. For example, in most fossils DNA is not present and the Jurrasic Park techniques to dinosaur blood from a mosquito trapped in amber, still remains wishful thinking.
>Read more in Dutch

Strategic Investment by SkylineDx in Cancer Vaccine Company DCPrime

Published : Tuesday, October 28, 2014

SkylineDx, an innovative company in the field of genetic testing for blood cancers, announced a strategic investment of an undisclosed sum in the Dutch cancer vaccine company DCPrime. The financing is designed to provide DCPrime with funding for the development of its technology platform and to take advantage of the synergies between the cancer companies.

Galapagos and Calchan collaborate on osteoarthritis research, £2.4 million grant awarded by Innovate UK

Published : Monday, October 27, 2014

Galapagos NV, a clinical stage biotech company focused on developing novel mode of action medicines, and Calchan Limited, a UK company focused on the development of novel medicines based on calcium ion channel modulators, announced that they have entered into a research collaboration in the area of osteoarthritis pain. 

LUMC Science Day

Published : Monday, October 27, 2014

Leiden Bio Science Park foundation was present at the LUMC Science Day at October 26th. The very popular open day consists of a large fair with LUMC departments, all kind of tests and lectures.
Leiden Bio Science Park foundation organised 4 lectures that accompanied the viewing of the Red carpet (Rode Loper) films about the chain of drug development at Leiden Bio Science Park.

Leiden Bio Science Park foundation visited Japan

Published : Saturday, October 25, 2014

Beginning of October Thijs de Kleer, director and Ellen Smit, senior account manager, both of the Leiden Bio Science Park foundation visited Japan. During this trip, they visited life sciences companies including AnGes, Daiichi Sankyo and Maruho. A small seminar was organized by the Osaka Pharmaceutical Manufacturers Association where Leiden Bio Science Park was presented to life science companies in Osaka.

Councillors and MPs visited Leiden Bio Science Park

Published : Tuesday, October 21, 2014

Members of the last March newly elected city council were invited for introductory programs by various stakeholders in the city, amongst whom the Leiden Bio Science Park foundation and the entrepreneurial society OV BSP.

Galapagos discloses novel target and presents favorable Phase 1 data for GLPG1205 at UEG Week

Published : Monday, October 20, 2014

Galapagos discloses GPR84 as a promising novel target for treating inflammatory bowel disease during an oral presentation at United European Gastroenterology Week in Vienna on 21 October.  Furthermore, Galapagos presents a poster disclosing favorable Phase 1 results with GLPG1205, the first clinical compound ever developed against target GPR84. 

CHDR proudly announces the establishment of a new research area: Translational Biomarkers

Published : Friday, October 17, 2014

Drugs that will be developed in the future will increasingly affect pathophysiological pathways that have been largely unexplored. Such drug prototypes cannot immediately be introduced in large clinical trials, but require rational exploration in tailored early phase clinical studies, with biomarkers that are fit-to-purpose.

Treeway and Leiden Academic Center for Drug Research collaborate

Published : Wednesday, October 15, 2014

Treeway and LACDR at the University of Leiden join forces and form a collaboration focused on the optimization of clinical trial designs and data-analysis for ALS (Amyotrophic Lateral Sclerosis) through the use of population disease progression models. Furthermore both parties aim to obtain a better understanding of the disease by developing ALS physiology-based disease models and to test the effect of interventions in the different identified pathways.

Volgende »


The Leiden Bio Science Park newsletter is a free bimonthly email newsletter in English. The newsletter offers general life science news, news from the companies and institutions, a company profile, events and jobs.
click here to subscribe